Abstract
ObjectivesCurrent guidelines recommend tapering biological disease-modifying antirheumatoid drugs (bDMARDs) in rheumatoid arthritis (RA) if the disease is under control. However, guidelines on tapering are lacking. Assessing cost-effectiveness of different tapering...
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have